Urinary Method Detects Toxin Exposure from Harmful Algal Blooms
By LabMedica International staff writers Posted on 29 Jan 2020 |
Image: The Q Exactive Hybrid Quadrupole-Orbitrap mass spectrometer (Photo courtesy of Thermo Fisher Scientific).
During harmful algal blooms (HABs), species of cyanobacteria release toxic peptides, including microcystins and nodularin into waterways, impacting wildlife and humans living in these marine environments.
Human exposure comes from ingestion, direct skin contact, or inhalation and can lead to a variety of symptoms ranging from gastroenteritis, nausea, allergic reactions and skin rashes to hepatic injury and hemorrhage in more severe cases. Microcystins also have been linked to tumor progression and are harmful to renal, immune and reproductive systems.
A group of scientists led by the Centers for Disease Control and Prevention (CDC, Atlanta, GA, USA) tested a newly developed immunocapture protein phosphatase inhibition assay (IC-PPIA) method for detection of microcystins and nodularin in human urine. This method uses a commercially available antibody to specifically isolate microcystins and nodularine from human urine prior to measurement. Urines from the Florida residents were self-collected by participants into sterile collection cups and stored at −80 °C until shipment to the Florida Atlantic University laboratory (Ft. Pierce, FL, USA).
The team used the Q Exactive Hybrid Quadrupole-Orbitrap mass spectrometer (Thermo Fisher Scientific, Waltham, MA, USA) to measure peak areas from the samples. The highly toxic MC congener microcystin-LR was resolved on an Agilent 1290 liquid chromatograph (Agilent Technologies, Santa Clara, CA, USA) using an Acquity UPLC BEH C18 column (Waters, Milford, MA, USA). A Protein Phosphatase Inhibition Assay was performed and the absorbance was read at 405 nm on a Powerwave HT microplate spectrophotometer (BioTek, Winooski, VT, USA).
The scientists demonstrated that the IC-PPIA method developed by the CDC was able to detect low-dose human exposures to microcystins by analysis of urine from three of the 86 urine specimens analyzed by this new method, which yielded positive results with concentrations of 0.055, 0.089 and 0.052 ng/mL MC-LR equivalents. These findings are the first to report microcystin concentrations directly from exposed residents impacted by cyanobacteria in Florida.
The authors concluded that they had described the development and application of an IC-PPIA for detection of nearly all microcystins (MCs) and nodularin (NOD) in human urine. Ten-fold sample concentration in this method makes it sensitive enough to detect even low-level human inhalation exposures to MCs and NOD. This method could complement water monitoring programs by identifying human exposures to MCs and NOD at the time of HABs and may assist in elucidating health effects associated with these toxins in the future. The study was published on December 19, 2019 in the journal Toxins.
Related Links:
Centers for Disease Control and Prevention
Florida Atlantic University
Thermo Fisher Scientific
Agilent Technologies
BioTek
Waters
Human exposure comes from ingestion, direct skin contact, or inhalation and can lead to a variety of symptoms ranging from gastroenteritis, nausea, allergic reactions and skin rashes to hepatic injury and hemorrhage in more severe cases. Microcystins also have been linked to tumor progression and are harmful to renal, immune and reproductive systems.
A group of scientists led by the Centers for Disease Control and Prevention (CDC, Atlanta, GA, USA) tested a newly developed immunocapture protein phosphatase inhibition assay (IC-PPIA) method for detection of microcystins and nodularin in human urine. This method uses a commercially available antibody to specifically isolate microcystins and nodularine from human urine prior to measurement. Urines from the Florida residents were self-collected by participants into sterile collection cups and stored at −80 °C until shipment to the Florida Atlantic University laboratory (Ft. Pierce, FL, USA).
The team used the Q Exactive Hybrid Quadrupole-Orbitrap mass spectrometer (Thermo Fisher Scientific, Waltham, MA, USA) to measure peak areas from the samples. The highly toxic MC congener microcystin-LR was resolved on an Agilent 1290 liquid chromatograph (Agilent Technologies, Santa Clara, CA, USA) using an Acquity UPLC BEH C18 column (Waters, Milford, MA, USA). A Protein Phosphatase Inhibition Assay was performed and the absorbance was read at 405 nm on a Powerwave HT microplate spectrophotometer (BioTek, Winooski, VT, USA).
The scientists demonstrated that the IC-PPIA method developed by the CDC was able to detect low-dose human exposures to microcystins by analysis of urine from three of the 86 urine specimens analyzed by this new method, which yielded positive results with concentrations of 0.055, 0.089 and 0.052 ng/mL MC-LR equivalents. These findings are the first to report microcystin concentrations directly from exposed residents impacted by cyanobacteria in Florida.
The authors concluded that they had described the development and application of an IC-PPIA for detection of nearly all microcystins (MCs) and nodularin (NOD) in human urine. Ten-fold sample concentration in this method makes it sensitive enough to detect even low-level human inhalation exposures to MCs and NOD. This method could complement water monitoring programs by identifying human exposures to MCs and NOD at the time of HABs and may assist in elucidating health effects associated with these toxins in the future. The study was published on December 19, 2019 in the journal Toxins.
Related Links:
Centers for Disease Control and Prevention
Florida Atlantic University
Thermo Fisher Scientific
Agilent Technologies
BioTek
Waters
Latest Clinical Chem. News
- 3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models
- POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection
- Highly Reliable Cell-Based Assay Enables Accurate Diagnosis of Endocrine Diseases
- New Blood Testing Method Detects Potent Opioids in Under Three Minutes
- Wireless Hepatitis B Test Kit Completes Screening and Data Collection in One Step
- Pain-Free, Low-Cost, Sensitive, Radiation-Free Device Detects Breast Cancer in Urine
- Spit Test Detects Breast Cancer in Five Seconds
- Electrochemical Sensors with Next-Generation Coating Advances Precision Diagnostics at POC
- First-Of-Its-Kind Handheld Device Accurately Detects Fentanyl in Urine within Seconds
- New Fluorescent Sensor Array Lights up Alzheimer’s-Related Proteins for Earlier Detection
- Automated Mass Spectrometry-Based Clinical Analyzer Could Transform Lab Testing
- Highly Sensitive pH Sensor to Aid Detection of Cancers and Vector-Borne Viruses
- Non-Invasive Sensor Monitors Changes in Saliva Compositions to Rapidly Diagnose Diabetes
- Breakthrough Immunoassays to Aid in Risk Assessment of Preeclampsia
- Urine Test for Monitoring Changes in Kidney Health Markers Can Predict New-Onset Heart Failure
- AACC Releases Comprehensive Diabetes Testing Guidelines